A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond, Lara Hatchuel, Min Dong, Brenda Ma, Branda Hu, Igor Smolenov, Ping Li, Peng Liang, Htay Htay Han, Joshua Liang, Ralf Clemens
doi: https://doi.org/10.1101/2020.12.03.20243709

Article usage

Article usage: December 2020 to January 2025

AbstractFullPdf
Dec 2020217351913
Jan 2021910119464
Feb 202148676199
Mar 20212714689
Apr 202129635102
May 20212892393
Jun 20214432276
Jul 202119910131
Aug 202118319126
Sep 202118718186
Oct 202110310141
Nov 20211231181
Dec 2021922064
Jan 2022842186
Feb 202292336
Mar 202275937
Apr 202257786
May 2022681274
Jun 202263338
Jul 202253360
Aug 202245361
Sep 202260337
Oct 202260136
Nov 202270259
Dec 202264716
Jan 202381216
Feb 202329813
Mar 202355010
Apr 202335318
May 202321412
Jun 202325611
Jul 20232157
Aug 2023381511
Sep 20236969
Oct 2023114515
Nov 2023208107
Dec 20232339
Jan 202419138
Feb 202432413
Mar 20243035
Apr 202427716
May 20242335
Jun 20242659
Jul 202425311
Aug 2024261018
Sep 202426315
Oct 2024281016
Nov 2024361425
Dec 202434214
Jan 202521111
Back to top
Posted December 04, 2020.
Download PDF
Data/Code
Email
A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial
Peter Richmond, Lara Hatchuel, Min Dong, Brenda Ma, Branda Hu, Igor Smolenov, Ping Li, Peng Liang, Htay Htay Han, Joshua Liang, Ralf Clemens
medRxiv 2020.12.03.20243709; doi: https://doi.org/10.1101/2020.12.03.20243709
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area